Does a GLP-1 reduce visceral fat after menopause?

# Does a GLP-1 reduce visceral fat after menopause?

After menopause, many women notice their weight settling in a new place, around the middle, even when the number on the scale has barely moved. That shift is not your imagination and it is not a willpower problem. It reflects a real change in where the body stores fat once estrogen falls. So it is a fair question to ask whether a weight medicine reaches the specific deep belly fat that menopause tends to add, rather than just trimming weight everywhere. This piece walks through what the evidence actually shows, and it is careful about where that evidence stops short.

Key takeaways

Dr. Linda's take

Women tell me the same thing in slightly different words. The weight is landing in my belly now, and it never used to. They want to know whether it is different fat, and whether a medicine can touch it specifically.

Here is the honest version. The menopausal shift toward deep belly fat is well described, and it matters for the heart, not only the mirror. On the medicine side, we do have randomised trials that scanned people with MRI and measured visceral fat going down, which is more than we can say for most weight claims. What we do not have is a clean trial that enrolled only postmenopausal women and proved the drug preferentially melts their visceral fat over everything else. So I will tell you the deep fat responds, and I will not pretend the studies were built around your exact stage of life. Those are two different statements, and I keep them separate.

If you want a starting point for whether any of this fits your situation, our eligibility quiz is one place to begin. It is general education, not a plan for you specifically.

Why does menopause add visceral fat?

The short answer is estrogen. When it falls, the body changes both how much fat it stores and where it puts it.

Menopause is associated with a natural decline in estrogen, that increases visceral fat mass, decreases bone mass density, muscle mass, and strength. The relocation starts early. During perimenopause, even in the context of minimal-to-modest weight gain, women experience an expansion of visceral adipose tissue, while the subcutaneous fat at the hips and thighs tends to shrink. And this really does track with the transition rather than simply with age. During the menopausal transition, only those women who became postmenopausal had a significant increase in visceral adipose tissue.

So the belly change is a hormone story with a specific fingerprint. Fat leaves the hips and thighs and gathers deep in the abdomen, and that pattern arrives with the menopausal transition itself.

Why is visceral fat the kind that matters?

Not all fat carries the same risk, and visceral fat sits at the wrong end of that scale.

Visceral fat is the deep fat packed around the abdominal organs, distinct from the subcutaneous fat that sits just under the skin. Its location is the problem. That redistribution toward visceral fat is associated with a greater prevalence of cardiovascular disease risk factors and a higher incidence of cardiovascular disease events. That is why the middle changing after menopause is a metabolic signal and not only a question of how clothes fit.

Does a GLP-1 target visceral fat specifically?

This is where the imaging trials help, because they measured the deep depot directly instead of guessing from the scale.

The most relevant study designed itself around exactly this question. In one randomised, double-blind, placebo-controlled trial, the primary endpoint was the percentage reduction in visceral adipose tissue measured with MRI. The population is worth noting for this topic. That trial enrolled adults with overweight or obesity at high cardiovascular risk, and its cohort was 92% female participants, 37% Black participants, and 24% Hispanic participants. And the deep fat moved. Mean change in visceral fat was a reduction of 12.49% with liraglutide 3.0 mg compared with a reduction of 1.63% with placebo, an estimated treatment difference of 10.86% in favour of liraglutide. The authors summarised it plainly. In adults with overweight or obesity at high cardiovascular disease risk, once-daily liraglutide 3.0 mg plus lifestyle intervention significantly lowered visceral adipose tissue over 40 weeks of treatment.

It is not only one medicine or one imaging study. In a separate MRI substudy, tirzepatide showed a significant reduction in liver fat content and in visceral and subcutaneous abdominal fat volumes compared with insulin degludec in people with type 2 diabetes. Across these trials the theme is consistent, the deep abdominal fat comes down when weight comes down on these medicines.

Why that might be worth caring about beyond the waistline is the last piece. The trial's authors noted that visceral fat reduction may be one mechanism to explain the benefits seen on cardiovascular outcomes in previous trials with liraglutide among patients with type 2 diabetes. That is a hypothesis about mechanism, not a promise, and I am labelling it as one.

What does this mean after menopause?

The honest read is encouraging and bounded at the same time.

These medicines drive real weight loss overall. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% on placebo. And when trials looked underneath the scale with imaging, the visceral compartment fell too, so the deep menopausal belly fat is within reach of the effect. The boundary is who was studied. The imaging trials above enrolled general adults with obesity or type 2 diabetes, not women selected for the menopause transition, so the fair claim is that visceral fat responds in mixed populations, and postmenopausal women were part of them rather than the sole focus. If regain after stopping is on your mind, our companion on weight after menopause if you stop this medicine covers that ground.

What should you know before starting?

The deep fat that menopause adds is the fat most tied to heart risk, which is part of why this question matters beyond appearance, and it connects to our companion on whether this medicine can lower heart disease risk after menopause. Reasonable questions for your own clinician include whether your personal cardiovascular risk makes visceral fat a priority, what a realistic pace looks like for your stage, and how to protect muscle and bone while losing weight. Whether this class of medicine is a fit for you at all is its own conversation, and we lay out more of the groundwork in our companion on weight gain after menopause. A licensed clinician who knows your history is the person to weigh it with.

Frequently asked questions

Does a GLP-1 reduce visceral fat after menopause?

The deep fat does respond in trials that measured it. Mean change in visceral fat was a reduction of 12.49% with liraglutide 3.0 mg compared with a reduction of 1.63% with placebo, an estimated treatment difference of 10.86% in favour of liraglutide. The caveat is that this and similar imaging trials studied general adult populations rather than women selected for menopause, so the effect is shown in mixed groups that included women, not proven to single out postmenopausal fat.

Is visceral fat really more dangerous than other fat?

Its location is what makes it risky. That redistribution toward visceral fat is associated with a greater prevalence of cardiovascular disease risk factors and a higher incidence of cardiovascular disease events. That is why the shift toward deep belly fat after menopause is treated as a metabolic signal, not just a change in shape.

Does menopause itself cause the shift to belly fat, or is it just aging?

It tracks with the transition. During the menopausal transition, only those women who became postmenopausal had a significant increase in visceral adipose tissue. So the deep fat gain lines up with becoming postmenopausal rather than with age alone.

Is this only shown for one medicine?

No. In a separate MRI substudy, tirzepatide showed a significant reduction in liver fat content and in visceral and subcutaneous abdominal fat volumes compared with insulin degludec in people with type 2 diabetes. So more than one medicine in this space has lowered visceral fat when imaging measured it directly.

References

1. Maltais ML, Desroches J, Dionne IJ. (2009). Changes in muscle mass and strength after menopause. PubMed / National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/19949277/ (Accessed 2026-07-25).
2. Perimenopausal and menopausal visceral adipose tissue expansion and gluteofemoral fat reduction (2026). PubMed / National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/41567597/ (Accessed 2026-07-25).
3. Lovejoy JC, Champagne CM, de Jonge L, et al. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. PubMed / National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/18332882/ (Accessed 2026-07-25).
4. Neeland IJ, Marso SP, Ayers CR, et al. (2021). Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk. PubMed / Lancet Diabetes and Endocrinology. https://pubmed.ncbi.nlm.nih.gov/34358471/ (Accessed 2026-07-25).
5. Gastaldelli A, Cusi K, Fernández Landó L, et al. (2022). Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue (SURPASS-3 MRI). PubMed / Lancet Diabetes and Endocrinology. https://pubmed.ncbi.nlm.nih.gov/35468325/ (Accessed 2026-07-25).
6. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). PubMed / New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-25).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-25.*